BEIJING, April 27, 2026 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2026 before the U.S. market opens on Thursday, May 28, 2026. Following the announcement, Weibo’s management team will host a conference call from 7 AM – 8 AM Eastern Time on May 28, 2026 (or 7 PM – 8 PM Beijing Time on May 28, 2026) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register-conf.media-server.com/register/BIb549b1f6935046d98b52a0fe61be918e

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com 

View original content:https://www.prnewswire.com/news-releases/weibo-corporation-to-report-first-quarter-2026-financial-results-on-may-28-2026-302754018.html

SOURCE Weibo Corporation

Expert-led clinical supply strategy powered by advanced planning and analytics technologies.

NOTTINGHAM, England and LASNE, Belgium, April 27, 2026 /PRNewswire/ — Perceptive eClinical, a leading provider of interactive response technology (IRT) and eClinical solutions, and Trialzen, an expert-led Forecasting and Supply Technology company, today announced an alliance supporting Perceptive eClinical in the launch of its Clinical Intelligence Consultancy Service, Perceptive Clinical Intelligence. This transforms its long–standing clinical supply expertise into a fully integrated, expert–led service spanning the entire clinical trial lifecycle and enabled by Trialzen’s advanced clinical supply planning technologies.

Perceptive Clinical Intelligence combines Perceptive’s deep expertise in randomization and clinical supply optimization with data-driven, technology enabled mathematical optimization, simulation, and forecasting to support smarter planning across the trial lifecycle. This integrated offering helps sponsors design, stress test, and manage clinical supply strategies with greater confidence and operational control. By formalizing its in-house expertise and therapeutic experience, Perceptive unifies randomization, trial supply management technologies and clinical supply consulting to enable more informed, scalable, and lower risk supply decision making.

“Clinical trial supply decisions are too critical to rely on tools alone,” said Malcolm Morrissey, Head of Perceptive Clinical Intelligence. “While supply discussions often focus on stock levels and overage, the real risk is patient impact. Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial.”

Industry benchmarks show that approximately 50% of Clinical Finished Goods (CFG) manufactured for clinical trials are never administered to patients, representing hundreds of millions of dollars in wasted drug supply each year1.

“Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive’s evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle,” said Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

Perceptive eClinical and Trialzen have each delivered proven results for sponsors, with real–world engagements generating savings exceeding $1 million and materially reducing supply overage.

A Technology Enabled, Expert-Led Approach

Delivered by Perceptive’s in–house specialists, the consultancy is built on 30 years of experience supporting biotech and large pharma across randomization and clinical supply management. It combines Perceptive’s proven supply–modelling expertise with Trialzen’s advanced calculation and simulation engine, fully integrated into Perceptive’s next–generation platform, Clinphone Pro.

Anchored in deep oncology expertise, where global scale, complex dosing, and multi–layered supply chains increase planning risk, the consultancy also draws on experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. 

Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: “Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop. This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step.”

At the heart of this alliance is a shared belief that clinical supply planning and execution should live in one connected environment. “Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day–to–day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing”. said Tony Street, Senior Vice President Strategy at Trialzen.

Clients benefit from:

Faster study start-up and smoother amendments through early supply optimizationHigher quality supply decisions driven by expert oversight and data backed insightGreater confidence through strategic expert consultancy for complex trialsMid-study forecast adjustments and up-to-date quantitative support for key decisions

About Perceptive eClinical

Perceptive eClinical is a trusted leader in delivering advanced trial capabilities. With over 30 years of proven Interactive Response Technology (IRT) and supply management expertise, more than 500 regulatory approvals and support for three million patients worldwide, we deliver reliability, security and precision. This is reflected in our consistently high customer satisfaction score of 4.5 out of 5 over the past three years. Our future-proof IRT solution, Clinphone Pro, helps sponsors manage the speed, complexity and personalization of modern clinical trials. Built for flexibility and seamless integration, it supports smarter, more efficient studies across all phases and therapeutic areas. In 2025, Perceptive eClinical was recognized as a leader in Everest Group’s PEAK Matrix® Assessment for RTSM Solutions, affirming our commitment to innovation, global delivery excellence and measurable value for sponsors and CROs.

About Trialzen

Trialzen is a technology company built by industry experts specializing in clinical trial supply forecasting and planning. Its Forecast & Planning Solution (FPS) is a purpose-built SaaS platform that enables sponsors and CROs to model, simulate, and optimize clinical supply strategies across the full trial lifecycle. Built by clinical supply experts, Trialzen combines advanced mathematical modelling and analytics with a transparent, user-friendly interface, allowing teams to evaluate scenarios, anticipate risk, and make informed supply decisions with speed and confidence. 

Sources

McKinsey & Company, Clinical Supply Chains insights

Media Contact: Zara Broadfield, Marketing Director Perceptive eClinical, zara.broadfield@perceptive.com 

Logo – https://mma.prnewswire.com/media/2965426/Perceptive_eClinical.jpg
Logo – https://mma.prnewswire.com/media/2965427/5936695/Trialzen.jpg

View original content:https://www.prnewswire.co.uk/news-releases/perceptive-eclinical-launches-technologyenabled-clinical-supply-consultancy-in-alliance-with-trialzen-302754074.html

SHANGHAI, April 27, 2026 /PRNewswire/ — As an authorized distributor, Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.

Last quarter, Mouser launched more than 9,000 part numbers ready for shipment. Some of the products introduced by Mouser from January through March 2026 include:

STMicroelectronics STM32C5 Arm® Cortex®-M33 Microcontrollers
The STM32C5 microcontrollers (MCUs) from STMicroelectronics are specifically designed to boost the performance of billions of tiny smart devices across factories, homes, cities, and infrastructure while meeting stringent cost, size, and power constraints. Based on ST’s proprietary 40 nm manufacturing process, the STM32C5 MCUs can run tasks noticeably faster than many entry-level chips currently in use. This gives products more room to include features such as improved sensing, smoother control, and enhanced user experiences while keeping dynamic power consumption low. The MCUs also integrate security features that help safeguard products against tampering and cyber risks.EDATEC ED-CM0NANO Single-Board Computer
The ED-CM0NANO is a single-board computer (SBC) from EDATEC, based on the Raspberry Pi Compute Module Zero (CM0). The ED-CM0NANO features a quad-core Arm Cortex-A53 processor running at up to 1 GHz, a Broadcom VideoCore-IV graphics processor, and a wide range of connectivity options. Optional Wi-Fi® support with an external antenna enables wireless connectivity, while integrated real-time clock (RTC) and watchdog timer enhance system reliability. These features make the ED-CM0NANO ideal for industrial control systems and Internet of Things (IoT) applications.Sensata Technologies MGD Resonix™ Refrigerant Leak Sensor
The MGD Resonix™ sensor from Sensata delivers high accuracy and fast response times in a compact module that fits into the smallest heating, ventilation, air conditioning (HVAC), and refrigeration equipment. The MGD series offers superior resistance to overexposure and poisoning, as well as to high temperatures (working temperatures up to 105 °C) and humidity. These devices also have a service life of more than 15 years with no need for calibration, making them the ideal leak-detection component for A2L HVAC and refrigeration systems.u-blox ANN-MB3 Triple-Band GNSS Antenna
The ANN-MB3 from u-blox is a best-in-class L1/L2/L5 triple-band RTK real-time kinematic (RTK) solution ideal for the F20 high-precision GNSS. Optimized for seamless integration, the ANN-MB3 antenna delivers exceptional performance with a robust design. The antenna’s compact (62 × 80 × 25.5 mm) form factor and flexible installation options enable the adoption of high-precision positioning technologies across industrial, automotive, and robotics applications.

To see more of the New Product Insider highlights, go to https://info.mouser.com/new_products/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-9-000-new-parts-added-in-first-quarter-of-2026–302754079.html

SOURCE Mouser Electronics